Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05156996 · ClinicalTrials.gov registry record
A Prospective Real-World Multi-Center Post-Market Observational Evaluation of Supersaturated O2 Therapy Using the TherOx® Downstream® System
A clinical trial, sponsored by TherOx.
- Terminated
- Registry status
- 6
- Enrollment target
NCT05156996: Clinical Trial study, sponsored by TherOx.
NCT05156996 is a clinical trial that was terminated before completion, run by TherOx. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05156996 was terminated before completion, sponsored by TherOx.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to collect real-world data on the TherOx DownStream System® to assess the effectiveness and cost- effectiveness of SSO2 Therapy, compared with PCI alone for treatment of patients with acute anterior MI.
Primary Outcome
Rate of Cardiovascular Death
Interventions
- DEVICE Supersaturated O2 Therapy of the Therox Downstream System®
- PROCEDURE PCI alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-12-04 |
| Est. Completion | 2024-04-24 |
Why NCT05156996 stopped before completion
NCT05156996 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Supersaturated O2 Therapy of the Therox Downstream System® is the first listed.
NCT05156996 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05156996 about?
NCT05156996 is a clinical study titled "A Prospective Real-World Multi-Center Post-Market Observational Evaluation of Supersaturated O2 Therapy Using the TherOx® Downstream® System". The purpose of this study is to collect real-world data on the TherOx DownStream System® to assess the effectiveness and cost- effectiveness of SSO2 Therapy, compared with PCI alone for treatment of patients with acute anterior MI.
What is the current status of trial NCT05156996?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2022-12-04. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT05156996?
The interventions under investigation include: Supersaturated O2 Therapy of the Therox Downstream System® (DEVICE), PCI alone (PROCEDURE).
Who is sponsoring clinical trial NCT05156996?
This trial is sponsored by TherOx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI